Aurobindo Pharma has acquired a portfolio of assets comprised of 45 ANDA’s, which includes oral solid, dermatological, and injectable generic products.

EAST WINDSOR, N.J. — Aurobindo Pharma has acquired a portfolio of assets comprised of 45 ANDA’s, which includes oral solid, dermatological, and injectable generic products. The products are not currently being marketed, though work has begun with regards to site and tech transferring the products to Aurobindo Pharma’s network of FDA approved facilities, as well as qualifying alternate API sources where it makes sense to do so.

In the meantime, reintroduction / relaunch plans are ongoing and the products will be commercialized over the next 12-24 months on a priority basis. Paul McMahon, resident of Oral Solids Division for Aurobindo Pharma USA, commenting on the news said, “This greatly expands Aurobindo’s breadth of line and expansive industry leading portfolio. Additionally, it further cements our long term commitment to serving the U.S. generic market, our customers, and the patients that rely on our life saving/improving pharmaceutical products.